AD Pipeline Update: Concerto Biosciences’ ENS-002 Shows Safety and Efficacy in Phase 1b Trial
Concerto Biosciences’ ENS-002, a topical three-strain live biotherapeutic product for mild-to-moderate atopic dermatitis (AD), showed promise in a first-in-human Phase 1b clinical trial, according to topline results.